Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer

Frontiers in Pharmacology
Anusha AndeSihem Ait-Oudhia

Abstract

Background: Emergence of Human epidermal growth factor receptor 2 (HER2) therapy resistance in HER2-positive (HER2+) breast cancer (BC) poses a major clinical challenge. Mechanisms of resistance include the over-activation of the PI3K/mTOR and Src pathways. This work aims to investigate a novel combination therapy that employs paclitaxel (PAC), a mitotic inhibitor, with everolimus (EVE), an mTOR inhibitor, and dasatinib (DAS), an Src kinase inhibitor, as a modality to overcome resistance. Methods: Static (two dimensional, 2D) and three-dimensional dynamic (3DD) cell culture studies were conducted using JIMT-1 cells, a HER2+ BC cell line refractory to HER2 therapies. Cell viability and caspase-3 expression were examined after JIMT-1 cell exposure to agents as monotherapy or in combination using a 2D setting. A pharmacokinetic/pharmacodynamic (PK/PD) combination study with PAC+DAS+EVE was conducted over 3 weeks in a 3DD setting. PAC was administered into the system via a 3 h infusion followed by the addition of a continuous infusion of EVE+DAS 24 h post-PAC dosing. Cell counts and caspase-3 expression were quantified every 2 days. A semi-mechanistic PK/PD model was developed using the 2D data and scaled up to capture the 3DD data...Continue Reading

References

Jan 1, 1982·Pharmacology & Therapeutics·N H Holford, L B Sheiner
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M F PressK J Flom
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Baselga, J Albanell
Sep 15, 2001·Clinical Pharmacology and Therapeutics·D E Mager, W J Jusko
Apr 3, 2004·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Scott M Dehm, Keith Bonham
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Dec 19, 2006·Oncogene·R C IshizawarS J Parsons
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ValabregaM Aglietta
Apr 3, 2007·Biologicals : Journal of the International Association of Biological Standardization·Hiroko Toriniwa, Tomoyoshi Komiya
Apr 11, 2007·The Journal of Pharmacology and Experimental Therapeutics·Dan LuJessie L-S Au
May 27, 2010·Molecular Cancer Therapeutics·Neil A O'BrienDennis J Slamon
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Apr 7, 2012·International Journal of Breast Cancer·Sahar ShojaeiAbbas Rahimi Shamabadi
Oct 23, 2012·The Breast : Official Journal of the European Society of Mastology·Dorte L NielsenMichael Andersson
Nov 2, 2012·The Journal of Pharmacology and Experimental Therapeutics·Sihem Ait-OudhiaDonald E Mager
May 8, 2013·International Journal of Cancer. Journal International Du Cancer·Feifei LiLili Wang
Jul 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J Gradishar
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neil A O'BrienDennis J Slamon
Dec 17, 2014·Translational Oncology·Richard BartlettAlexander M Seifalian
May 16, 2015·Molecular Medicine Reports·Juan XiaoJundong Li
Oct 25, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Sihem Ait-Oudhia, Donald E Mager

❮ Previous
Next ❯

Methods Mentioned

BETA
protein assay
Assay
biopsy

Software Mentioned

Xcalibur

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.